NKTR · Nektar Therapeutics
Conviction · Low · more likely to lag the S&P 500 over the next three months
Wrong if: a daily close above $49.97
Note written ·
Price against the kill line
25.4% clear of its kill line on the 13 November 2026 close.
How to read this
This note expects the shares to lag the market, so its kill line sits above the price: a close above the red mark would prove the view wrong. Prices run from low on the left to high on the right. The dot is where the stock closed on 13 November 2026, left of the mark while it is below the line; a dot right of the mark has closed through it.
The scale is stretched near the line, so close calls are easy to see. More than 8% from the line, the stock reads well clear, with a hollow dot to show the figure is off the drawn scale.
The kill line is the research note's own test. The portfolio sells on business facts, not on a price. How the portfolio decides
Three months against the kill line
Daily closes, to . Red: the kill line, a daily close above $49.97, on record since 11 November 2026. The shares are down 48.7% since the close; the S&P 500 is down 2.1% over the same sessions. Figures in the note can cover a different window.
Kill line
A daily close above $49.97, which would put the shares back above their 50-day average and show them leading the S&P 500. A result that would also show it: 24-week off-treatment alopecia data with response rates above the 63% reported at six months.
Research onlyNot in the portfolio.
The business · as of
Nektar develops rezpegaldesleukin, a Treg-selective interleukin-2 drug for atopic dermatitis and alopecia areata. It has no product sales; revenue is legacy royalty and collaboration income, $9.4 million in the quarter to 30 September 2026, and operations are funded by equity raised.
What is changing, and what follows · as of
- What is changing now
- On 12 November 2026 Nektar reported third-quarter sales of $9.386 million against a $10.274 million estimate, a loss of $1.63 per share against $2.08, and $952.9 million of cash and investments.
- What follows for the company
- The 10-Q filed 13 November 2026 shows an operating margin of −615.8% and free cash flow of −$257 million over four quarters; Nektar guided year-end 2026 cash to $815–840 million on 13 August 2026.
- What follows for its customers, suppliers and competitors
- Eli Lilly (LLY) faces post-trial motions on the $90 million award. Regeneron (REGN) and Sanofi (SNY) market Dupixent, the established biologic in atopic dermatitis that rezpegaldesleukin would compete with.
What the price assumes · as of
At the 13 November 2026 close (filed inputs to 13 November 2026) the shares trade at 12.7 times sales and 1.5 times book value, for an enterprise value of $661 million with no debt reported; P/E and EV/EBIT are not meaningful. That holds only if the Phase 3 programs justify a free-cash-flow yield of −20.2% on revenue of $9.4 million a quarter.
Key figures from the filings · Health Care
Quarter to 30 September 2026, filed 13 November 2026; valuation at the 13 November 2026 close
- Revenue, latest quarter ($M)
- 9.4
- Revenue, change on a year (%)
- −20.4
- Gross margin (%)
- 100.0
- Operating margin (%)
- −615.8
- Free cash flow, four quarters ($M)
- −258
- Net cash, cash less debt ($M)
- 614
- Enterprise value to sales (×)
- 12.7
- Free-cash-flow yield (%)
- −20.2
All filed numbers
What Nektar Therapeutics reports to the SEC in its quarterly and annual filings. Each group states its period and filing date once; a figure dated otherwise says so. Built from the filings known on .
| Quarter to | Revenue ($M) | On a year (%) | Gross margin (%) | Operating margin (%) |
|---|---|---|---|---|
| first filed | 9.4 | −20.4 | — | −615.8 |
| first filed | 10.1 | −9.3 | — | −417.9 |
| first filed | 10.9 | +3.8 | — | −359.6 |
| first filed | 21.8 | −25.3 | 100.0 | −126.9 |
| first filed | 11.8 | −51.1 | 100.0 | −268.6 |
| first filed | 11.2 | −52.4 | 100.0 | −324.2 |
| Pre-tax income ($M) | −55.0 |
| Net income ($M) four quarters: −177 | −55.7 |
| Diluted shares, change on a year (%) against the quarter to 30 September 2025 | +80.4 |
| Operating cash flow ($M) | −257 |
| Capital spending ($M) | 0.5 |
| Free cash flow ($M) | −258 |
| Cash and short-term investments ($M) | 614 |
| Debt ($M) | None reported |
| Net cash, cash less debt ($M) no debt reported | 614 |
| Deferred revenue ($M) | Not reported |
| Backlog, orders not yet delivered ($M) | Not reported |
| Receivables ($M) | Not reported |
| Inventory ($M) at 31 December 2025, filed 13 March 2026 | 0.0 |
| Shareholders' equity ($M) | 850 |
| Market value ($M) | 1,275 |
| Enterprise value, market value plus net debt ($M) no debt reported | 661 |
| Enterprise value to sales (×) no debt reported | 12.7 |
| Enterprise value to operating income (×) | Not meaningful |
| Price to earnings (×) | Not meaningful |
| Price to book value (×) | 1.5 |
| Free-cash-flow yield (%) | −20.2 |
Short interest (FINRA, settled 15 October 2026, published 26 October 2026): 20.4% of shares outstanding sold short, 3.5 days of average trading to cover, +0.4% since the previous report.
| Window | Bought | Sold |
|---|---|---|
| 90 daysfrom | $0 | $43K |
| 12 monthsfrom | $0 | $2.4M |
Linked companies · as of
The thesis
Nektar Therapeutics, a pre-commercial immunology developer, is more likely to lag the S&P 500 than lead it over the next three months. The shares closed at $37.27 on 13 November 2026, flat against $37.25 the session before, so the third-quarter report of 12 November 2026 did not turn them, and the market's doubt about alopecia durability is still unanswered. The 24-week off-treatment alopecia data, expected in the fourth quarter of 2026, settle it.
The three-month change is −48.7%. The 13 November 2026 close is below the 50-day average of $48.47 and the 200-day average of $65.05, and 65.8% below the 52-week intraday high of $109.00 reached on 20 April 2026. Wedbush cut its price target to $40 from $50 on 13 November 2026, after the report.
Bullish and bearish views on Nektar Therapeutics
The bull case on Nektar Therapeutics (NKTR), in brief: cash funds the Phase 3 programs. The bear case: the business burns cash on thin revenue.
Bull case
- Cash funds the Phase 3 programs. Nektar reported $952.9 million of cash and investments at 30 September 2026, against $1,023.4 million at 30 June 2026 (third-quarter results, 12 November 2026; second-quarter results, 13 August 2026). The 10-Q filed 13 November 2026 lists cash and short-term investments of $614 million with no debt reported. In August the company guided year-end 2026 cash to $815–840 million and said that funds operations into the third quarter of 2028.
- The loss per share was narrower than expected. The third-quarter loss was $1.63 per share against a $2.08 estimate (company news feed, 12 November 2026).
- A court award would add cash. On 24 September 2026 a jury found Lilly (LLY) breached the implied covenant of good faith and fair dealing in the rezpegaldesleukin license and awarded Nektar $90 million plus interest (Nektar release, 25 September 2026). Post-trial motions and an appeal remain possible.
- Late-stage work is under way. The first two atopic-dermatitis Phase 3 trials began in July 2026, and the company targets a biologics license application in 2029.
Bear case
- The business burns cash on thin revenue. The 10-Q for the quarter to 30 September 2026 shows revenue of $9.4 million, down 20.4% from a year earlier, an operating margin of −615.8% and a net loss of $56 million. Free cash flow was −$257 million over the four quarters to 30 September 2026. Revenue is legacy royalty and collaboration income, not product sales.
- Revenue missed the estimate. Third-quarter sales were $9.386 million against a $10.274 million estimate (company news feed, 12 November 2026).
- The share count keeps growing. The diluted share count rose 80.4% from a year earlier in the quarter to 30 September 2026 (10-Q, filed 13 November 2026). Nektar raised $373.8 million net in an April 2026 follow-on.
- Alopecia durability rests on small cohorts. Press coverage of the 1 October 2026 data reported 63% of responders holding a Severity of Alopecia Tool (SALT) score of 20 or better six months off drug, down from 75% at 52 weeks. Biotech Distilled reported 1 of 10 patients responding in a 36-week cohort under a stricter imputation method. The samples are too small to support a firm conclusion in either direction.
- Insiders have not bought on the open market. SEC Form 4 filings show director grants of 2,000 shares each on 23 September 2026, and open-market sales of 418 shares by CEO Howard Robin and 186 shares by Chief R&D Officer Jonathan Zalevsky at $71.98 on 18 August 2026.
- Securities class actions are pending. Suits covering 26 February to 15 December 2025 remain open.
Price setup
The shares closed between $37.25 and $38.44 in the six sessions from 6 November to 13 November 2026, ending at $37.27. That range sits just above the 52-week closing low of $35.12 set on 5 February 2026. The three-month reference close was $72.67 on 17 August 2026.
The 50-day average of $48.47 and the 200-day average of $65.05, both as of the 13 November 2026 close, sit well above the last close. Across US stocks trading at least $5 million a day, the spread of 63-session returns (standard deviation) was 27% in 2026, so a three-month move of this size is large even against a wide market spread.
The report came after the 12 November 2026 close. The 13 November 2026 close of $37.27 is the first that reflects it, and the shares did not move.
Catalysts ahead
- ~31 December 2026 (est.): 24-week off-treatment alopecia areata data from the Resolve AA study, flagged for the fourth quarter of 2026 in an earnings preview. Durability is the market's central doubt; response rates above the 63% six-month figure would challenge the lag call.
- ~31 March 2027 (est.): Planned start of the alopecia areata Phase 3. A slip would raise the chance the program needs financing inside the stated third-quarter 2028 runway.
- ~30 June 2028 (est.): Initial atopic-dermatitis Phase 3 topline data for rezpegaldesleukin. The next company-generated efficacy result; a biologics license application is targeted for 2029.
What would change the view
A daily close above $49.97, which would put the shares back above their 50-day average and show them leading the S&P 500. A result that would also show it: 24-week off-treatment alopecia data with response rates above the 63% reported at six months.
What it trades with
Nektar trades on its own pipeline events and on small- and mid-cap biotech sentiment. It has no product revenue, so moves in interest rates and the biotech index reach it through financing expectations. The Lilly litigation and the alopecia data are company-specific, and no current group of peers drives its business.
The evidence, claim by claim (8)
- Third-quarter loss was $1.63 per share against a $2.08 estimate; sales were $9.386 million against a $10.274 million estimate; cash and investments were $952.9 million. Company news feed, third-quarter 2026 results · as of
- Revenue of $9.4 million in the quarter to 30 September 2026, down 20.4% from a year earlier; operating margin −615.8%; net loss $56 million. Nektar 10-Q filed 13 November 2026 · as of
- Free cash flow was −$257 million over the four quarters to 30 September 2026; cash and short-term investments $614 million, no debt reported; diluted share count up 80.4% from a year earlier. Nektar 10-Q filed 13 November 2026 · as of
- Wedbush cut its price target on Nektar to $40 from $50. Company news feed, 13 November 2026 · as of
- Guided year-end 2026 cash of $815–840 million, funding operations into the third quarter of 2028; cash and investments were $1,023.4 million at 30 June 2026. Nektar second-quarter 2026 results, 13 August 2026 · as of
- Jury found Lilly breached the implied covenant of good faith and fair dealing in the rezpegaldesleukin license and awarded Nektar $90 million plus interest. Nektar release 25 September 2026 · as of
- CEO Howard Robin sold 418 shares and Chief R&D Officer Jonathan Zalevsky sold 186 shares at $71.98 on 18 August 2026. SEC Form 4 filings, 20 August 2026 · as of
- Closed at $37.27 on 13 November 2026, 65.8% below the 52-week intraday high of $109.00 (20 April 2026); three-month change −48.7%. Adjusted daily closes · as of
Sources